Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ATAI Life Sciences NV ATAI

Healthcare Biotechnology
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B... see more

Recent & Breaking News (NDAQ:ATAI)

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

GlobeNewswire December 14, 2021

atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

GlobeNewswire December 13, 2021

atai Life Sciences launches TryptageniX to further expand atai's robust intellectual property portfolio and strengthen atai's supply chain

GlobeNewswire December 9, 2021

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

GlobeNewswire November 29, 2021

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 15, 2021

atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update

GlobeNewswire November 8, 2021

atai Life Sciences to Participate in Upcoming November Investor Conferences

GlobeNewswire November 5, 2021

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia

GlobeNewswire November 1, 2021

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change

GlobeNewswire October 19, 2021

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

GlobeNewswire October 11, 2021

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder

GlobeNewswire September 21, 2021

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

GlobeNewswire September 15, 2021

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

GlobeNewswire September 14, 2021

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

GlobeNewswire September 9, 2021

atai Life Sciences to Participate in Upcoming September Investor Conferences

GlobeNewswire September 3, 2021

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

GlobeNewswire August 16, 2021

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

GlobeNewswire August 12, 2021

atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update

GlobeNewswire August 9, 2021

atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference

GlobeNewswire August 6, 2021

atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai's platform of mental health therapeutic programs

GlobeNewswire July 28, 2021